Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

Harrow has entered into an agreement with Samsung Bioepis for the U.S. commercial rights to two ophthalmology biosimilars, ...

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

The Food and Drug Administration's oncologic drugs advisory committee on voted against approval of GSK's blood cancer drug Blenrep. The British pharmaceutical company said Thursday combinations for ...

U.S. Market Leads with 74% Share in 2023 Valued at USD 2.71 Billion, Driven by Biotech Innovation, Favorable FDA Approvals, and Rising Chronic Disease Incidence.Austin, July 18, 2025 (GLOBE NEWSWIRE) ...